GlassScriptPhysician profile
Nikhita Dharbhamulla
NPI 1255715090
$7,905.60
in general payments reported to CMS, 2019-2025
26 companies · $3,272 in 2025
The $3,272 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.08 · 2020: $29.21 · 2021: $103 · 2022: $772 · 2023: $1,411 · 2024: $2,235 · 2025: $3,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,893 · Education: $25.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,892.82 |
| Education | $25.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,096.74 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,017.41 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $716.83 | 2022-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $606.48 | 2022-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $389.16 | 2023-2025 | |
| Qol Medical, LLC | $382.07 | 2023-2025 | Sucraid |
| Celgene Corporation | $370.80 | 2022-2024 | Zeposia |
| Genzyme Corporation | $342.73 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $328.42 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $313.51 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $167.83 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $165.53 | 2023-2025 | Linzess |
| Daiichi Sankyo INC. | $164.29 | 2022-2025 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $163.55 | 2024-2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $141.60 | 2024-2025 | Voquezna |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $119.99 | 2023 | Epclusa |
| Lilly USA, LLC | $93.48 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $65.71 | 2024-2025 | Vegzelma |
| Aimmune Therapeutics, INC. | $50.06 | 2023-2025 | Zenpep |
| Braintree Laboratories, INC. | $48.70 | 2022-2024 | Suflave, Sutab |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.23 | 2024 | Cyltezo |
| Sandoz INC. | $35.60 | 2024-2025 | Hyrimoz |
| Intercept Pharmaceuticals, INC. | $32.69 | 2023-2024 | Ocaliva |
| Romark Laboratories, Lc | $29.21 | 2020 | |
| Nestle Healthcare Nutrition INC. | $13.50 | 2022 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikhita Dharbhamulla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.